StreetAlpha.app
Home › Stocks › XFOR

X4 Pharmaceuticals, Inc (XFOR)

Healthcare
$3.00
▲ +1.35%
LAST CLOSE · NOV 20

X4 Pharmaceuticals develops and sells oral treatments for rare blood diseases, led by XOLREMDI (mavorixafor) for WHIM syndrome. It last closed at $3.00 on Nov 20, up 1.35% on the day. For the quarter ended Sep 2026, XFOR reported EPS of -$0.16 on revenue of $2.8M, with revenue up 75.0% from a year ago. Over its last 8 reports the stock moved an average of 17.0% the session after earnings. Over the last 12 months XFOR insiders bought $12K of stock on the open market and sold $463K, according to SEC Form 4 filings.

AI Auto Pilots
Is XFOR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold XFOR.

Key Stats

Last 12 months
Results
Revenue
$9.8M
+69.0% vs a year ago
Net income
−$80.5M
−821.6% margin
Gross margin
68.4%
$6.7M gross profit
Operating margin
−820.3%
−$80.4M operating income
Valuation
Market cap
$306.3M
102.1M shares
P/E
–
Price to sales
31.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$185.8M
At Sep 30
Debt
$75.0M
At Sep 30
Shareholder equity
$138.9M
Shares outstanding
102.1M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $2.6M$2.6MFY2024FY2025: $6.5M$6.5MFY2025

From XFOR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2025 · next date not set yet
Reported EPS
-$0.16
Quarter ended Sep 2026
Year ago EPS
-$0.69
Same quarter last year
Revenue
$2.8M
+75.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$5.94Dec '24Mar 2025: $0.04Mar '25Jun 2025: -$3.47Jun '25Sep 2025: -$0.69Sep '25Dec 2025: $1.00Dec '25Mar 2026: -$0.16Mar '26Jun 2026: -$0.13Jun '26Sep 2026: -$0.16Sep '26Latest -$0.16
Revenue by quarter
Dec 2024: $1.5MDec '24Mar 2025: $900,000Mar '25Jun 2025: $1.7MJun '25Sep 2025: $1.6MSep '25Dec 2025: $2.2MDec '25Mar 2026: $2.5MMar '26Jun 2026: $2.4MJun '26Sep 2026: $2.8MSep '26Latest $2.8M
How XFOR moved after its last 8 reports
Average move the session after a report ±17.0%
Nov 5, 2025Time not announced−10.6%
May 1, 2025Time not announced−13.0%
Mar 25, 2025Time not announced−12.1%
Nov 13, 2024Time not announced−53.2%
Aug 8, 2024Time not announced+3.2%
May 7, 2024Time not announced−9.2%
Mar 21, 2024Time not announced+28.4%
Nov 9, 2023Time not announced+6.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on XFORStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on XFOR
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on XFOR

Technical Analysis

XFOR · as of the Nov 20 close · updated each morning
Downtrend

The stock is 6% below its 20 day and 3% below its 50 day average. It is 25% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 46). The nearest support is the Pivot at $2.98, and the nearest resistance the Pivot R1 at $3.08.

Short trendBearish
Long trendBearish
MomentumFading
StretchNormal
VolatilityHigh, 8.1%/day
Key levels
$4.8352 week high+61.0%
$3.76200 day average+25.3%
$3.55100 day average+18.3%
$3.46Swing high (Nov 9)+15.3%
$3.1820 day average+6.0%
$3.0950 day average+3.0%
$3.08Pivot R1+2.7%
$3.00Last close
$2.98Pivot−0.7%
$2.91Pivot S1−3.0%
$2.90Swing low (Nov 5)−3.3%
$2.4352 week low−19.0%
Indicators
RSI (14)45.78Middle of its rangeNeutral
MACD-0.04Below its signal lineBearish
Stochastic30.2Middle of its rangeNeutral
ADX (14)17.0No clear trend
Williams %R-66.7Oversold below −80, overbought above −20Neutral
CCI (20)-99.5Oversold below −100, overbought above 100Neutral
Rate of change−5.7%Change over 10 sessionsBearish
ATR (14)$0.24Typical daily range, 8.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for XFOR

What happened before

See how XFOR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow XFOR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How XFOR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for XFORHow many large options trades hit XFOR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

XFOR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲51 buying vs 34 selling
  • ▲Held by funds +2.9 pts
  • ▲Funds holding +8
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9789+9.0%
In funds' top 1035−40.0%
Held by funds106.1%103.2%+2.9 pts
New / increased14 / 3732 / 25−10.5%
Reduced / sold out28 / 612 / 27−12.8%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See XFOR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

XFOR Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$12K1 buy · 1 insider
Sold$463K5 sales · 3 insiders
2026-05 sold $73K2026-06 sold $36K2026-08 sold $320K2026-10 bought $12K2026-10 sold $34KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 16Adam R CraigExecutive ChairmanBuy4,600$2.58$12K
Oct 1David KirskeCFOSale11,767$2.86$34K
Aug 12Adam R CraigExecutive ChairmanSale47,436$4.44$211K
Aug 12John VolponePresidentSale24,576$4.44$109K
Jun 30David KirskeCFOSale8,543$4.26$36K
May 12David KirskeCFOSale16,961$4.29$73K
Every insider buy and sale for XFOR over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See XFOR insider trades →

From SEC Form 4 filings by XFOR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XFOR is in one of them and how their past XFOR trades turned out.

XFOR in the AI portfolios
Loading…

XFOR News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered XFOR in an article yet. Here's the latest on the wider market.

XFOR in the news

About X4 Pharmaceuticals

X4 Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, that develops and sells treatments for rare blood diseases. Its main product, XOLREMDI (mavorixafor), is an oral capsule approved in the United States for WHIM syndrome, a rare immune disorder, and patients can obtain it through a specialty pharmacy. The company is also developing mavorixafor for chronic neutropenia, a rare blood condition, and works with partners to commercialize its products outside the United States.

Headquarters
Boston, MA